Introduction

Frohlich syndrome, also known as adiposogenital dystrophy, Babinski-Frohlich syndrome, dystrophia adiposogenitalis, hypothalamic infantilism (obesity), and Launois-Cleret syndrome, is a rare endocrine disorder caused by damage in the hypothalamus. The hypothalamus is a part of the brain that connects the nervous system with the endocrine system through the pituitary gland. It plays a key role in regulating body functions such as hormone release, body temperature, and sleep cycles.¹ Unlike many rare diseases, Frohlich syndrome is acquired after birth rather than inherited. It primarily affects people assigned male at birth (AMAB) and is often associated with hypothalamic tumours.

Insulin resistance occurs when muscles, fat, and liver cells fail to effectively absorb the glucose from the blood due to an improper insulin response. This leads to increased insulin production by the pancreas in response to this. While blood glucose may remain normal initially, prolonged insulin resistance can contribute to metabolic disorders. Understanding the connection between insulin resistance and Frohlich syndrome is crucial for the effective management and prevention of related complications. 

Pathology of frohlich syndrome

Frohlich syndrome is a rare metabolic condition that primarily affects children. Its major symptoms include growth retardation, obesity, and delayed genital organ development. This condition is strongly associated with hypothalamic tumours and generally results in decreased gonadotropin release and increased hunger. Alfred Frohlich, an Austrian neurologist, was the first one to identify this typical pattern, and so he was honoured with the disease’s name.

This particular condition is very common in AMAB compared to people assigned female at birth (AFAB). Also, there is a decrease in the pituitary function due to its close relationship with the hypothalamus. Most of the time the tumour enlarges in size and gets compressed and puts pressure against the neighbouring tissues and nerves, and in this process, the optic nerve might get affected and eventually get damaged. This might result in impairment of the vision.

The condition is caused by numerous organic lesions in the hypothalamus, most commonly in the infundibular-tubercular region, These lesions may result from:

• Tumours in the hypothalamus
• Encephalitis
• Friedreich ataxia
• Demyelinating diseases

Since the hypothalamus regulates the pituitary gland, damage to this region affects pituitary hormone secretion, leading to disruption in:²

• Blood pressure regulation
• Growth and metabolism
• Thyroid and adrenal gland functions
• Sex hormone production
• Energy balance and body temperature

Tumour growth can also compress surrounding tissues, including the optic nerve, causing visual impairment or blindness.

Insulin resistance

Insulin resistance is a condition in which body cells fail to respond properly to insulin, leading to a compensatory increase in insulin production. The primary affected tissues are adipose (fat), muscle, and liver. This results in metabolic disturbances such as:

• Hyperglycaemia (high blood sugar)
• Hypertension (high blood pressure)
• Dyslipidemia (abnormal cholesterol levels)
• Hyperuricemia (high uric acid levels)
• Chronic inflammation
• Endothelial dysfunction (blood vessel damage)

Over time, insulin resistance can lead to type 2 diabetes mellitus, which usually develops ten to fifteen years after the onset of insulin resistance.

Management of insulin resistance

Insulin resistance can be controlled by nutritional intervention, which generally involves reducing calorie intake, limiting carbohydrates, and avoiding high-glycaemic index foods. Engaging in physical activity can enhance insulin sensitivity by increasing glucose uptake in muscles. Additionally, medications such as metformin, glucagon-like peptide (GLP-1) agonists, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, and thiazolidinediones can help manage insulin resistance.³

The connection between frohlich syndrome and insulin resistance

Hypothalamic dysfunction disrupts nutritional homeostasis, leading to endocrine and metabolic imbalances. It can affect:

• Insulin secretion
• Hepatic glucose production
• Energy expenditure
• Glucose and fatty acid metabolism

Studies have linked hypothalamic inflammation to diabetes, obesity, and metabolic disorders.⁴ Hypothalamic obesity is a key consequence, resulting from damage to neural circuits that regulate body weight and energy balance.^5,6  Numerous endocrine dysfunctions like hyperleptinemia, hyperinsulinemia, a decrease in melatonin production, and a lowered basal metabolic rate have been linked with hypothalamic obesity.⁷   

Mechanisms linking hypothalamic dysfunction and insulin resistance

• Hypothalamic injury leads to increased appetite and fat storage, causing obesity⁸
• Obesity contributes to insulin resistance through chronic inflammation and metabolic dysregulation⁸
• Visceral fat accumulation leads to beta-cell dysfunction, dyslipidemia, and adipokine (cytokines released by adipose tissues) imbalances, promoting insulin resistance and type 2 diabetes⁸
• High-fat diets and prolonged hypothalamic inflammation exacerbate insulin resistance⁸

Non-neuronal cells, such as microglia and astrocytes, play a role in hypothalamic inflammation, leading to glucose intolerance and insulin resistance.

Clinical implications

Challenges in diagnosing and management

Diagnosis of Frohlich syndrome requires a combination of the following:

• Clinical assessment: obesity, delayed puberty, and endocrine dysfunction
• Laboratory tests: low gonadotropin levels and abnormal glucose
• Imaging studies: MRI and CT scans to detect hypothalamic tumours

Since Frohlich syndrome increases the risk of insulin resistance, regular monitoring for metabolic complications is essential. If untreated, patients with both conditions are at high risk for many serious diseases, like type 2 diabetes, cardiovascular diseases, hypertension, and dyslipidemia. Early intervention and continuous monitoring are necessary to prevent severe complications.

Treatment strategies

Treatment for frohlich syndrome

Treatment for Frohlich syndrome usually includes the removal of the tumours surgically that are present in the hypothalamus. Moreover, pituitary extracts can be given through hormone replacement therapy (HRT), where the lost hormones are replenished. The human chorionic gonadotropin is typically used in combination with testosterone in males to induce puberty. For females, the HRT involves progesterone with oestrogen. Weight control is dependent on the effective management of appetite. Glucagon-like peptide-1 analogues can be used for obesity management.

Management of insulin resistance

The cornerstone of insulin resistance is lifestyle change, which includes calorie restriction and decreasing high glycaemic index, managing carbohydrates, fat loss, salt reduction, glucose index monitoring, etc. Exercise increases insulin sensitivity and calorie expenditure in muscle tissue.³ 

Pharmacological treatments that are FDA-approved are metformin (reduces glucose production), glucagon-like peptide-1 analogues (controls appetite and glucose levels), sodium-glucose cotransporter-2 inhibitors (enhances glucose excretion), thiazolidinediones or dipeptidyl peptidase-4 (DPP-4) inhibitors (prolong insulin action).³

Summary

Frohlich syndrome is a rare endocrine disorder primarily affecting children. The major symptoms include growth retardation, obesity, and delayed puberty. It is linked with hypothalamic damage, leading to hormonal imbalances. Whereas, insulin resistance is a metabolic disorder where cells fail to respond to insulin; as a result, the level of insulin rises, leading to hyperglycemia, hypertension, dyslipidemia, hyperuricemia, increased inflammatory markers, endothelial dysfunction, prothrombotic states, etc. Hypothalamic dysfunction plays a critical role in the development of both conditions, particularly by promoting obesity and metabolic dysregulation. Early diagnosis, lifestyle modifications, and appropriate pharmacological treatments are essential to prevent severe complications and improve patient outcomes.